PCSK9 as target for treatment: the genetic validation.

25 August 2018 (15:35 - 15:50)

Organised by:

About the speaker

Professor Brian A Ference

University of Cambridge, Cambridge (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail

Introduction - PCSK9 inhibition: science, outcomes and guidance.

Professor P. Barter (Sydney, AU) Professor J. Kastelein (Amsterdam, NL)

Presentation thumbnail

Novel PCSK9 outcomes in perspective: lessons from FOURIER & ODYSSEY.

Doctor J. Robinson (Iowa, US)

Presentation thumbnail

Targeting PCSK9 in clinical practice: guidance and future.

Professor J. Kastelein (Amsterdam, NL)

Presentation thumbnail

Discussion and summary - PCSK9 inhibition: science, outcomes and guidance

Professor P. Barter (Sydney, AU)

Access the full session

Session thumbnail

PCSK9 inhibition: science, outcomes and guidance (EBAC Accredited)

The Event

ESC Congress 2018

25 August 2018 15:35 CET

You may be interested in

Congress Presentation

Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study

27 August 2021

Congress Session

Present and the future of PCSK9 inhibition in cardiovascular prevention: from antibodies to gene editing

30 August 2026

Congress Presentation

GLP1-RA associated with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences

20 June 2025

Congress Presentation

Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials

27 August 2022

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources